Navigation Links
FDA approves Bystolic, a novel beta blocker

The U.S. Food and Drug Administration (FDA) has approved Bystolic (nebivolol) for the treatment of hypertension, also known as high blood pressure. Hypertension affects approximately 72 million adults in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range (blood pressure <140/90 mmHg), underscoring the need for additional therapeutic options.

Bystolic, a novel beta blocker, is a once-daily medication that can be used as monotherapy or in combination with other anti-hypertension treatments to reduce blood pressure with a low incidence of traditional beta blocker side effects. Bystolic works differently than many older beta blockers in that it is preferentially beta 1 selective at doses less than or equal to 10 mg, meaning it selectively blocks the effects of adrenaline at the heart. In addition, Bystolic vasodilates or widens and expands - the blood vessels.

Bystolic, marketed in the U.S. by Forest Laboratories, Inc (NYSE: FRX), will be available in pharmacies nationwide in January 2008. For additional information, visit or call 1-800-678-1605.

Hypertension Statistics:

  • The number of people with high blood pressure is expected to reach about 1.6 billion worldwide by 2025

  • Some individuals are at increased risk based on age, race, lifestyle, body mass index/obesity and family history

  • More than half of all Americans aged 60 and older have high blood pressure

  • Men over the age of 45 are at increased risk

  • Women over the age of 55 are at increased risk

  • Hypertension greatly increases the risk of certain health problems such as stroke, heart attack and kidney failure

  • Blacks are at a greater risk for developing hypertension than Caucasians

  • Most patients need two or more classes of hypertension medications to effectively control their condition


Contact: Maria Dottori
Fleishman-Hillard, Inc.

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: